State Street Corp grew its holdings in Crispr Therapeutics AG (NASDAQ:CRSP) by 2.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,103 shares of the company’s stock after purchasing an additional 758 shares during the quarter. State Street Corp owned approximately 0.07% of Crispr Therapeutics worth $1,521,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. BSW Wealth Partners acquired a new position in shares of Crispr Therapeutics during the 2nd quarter worth approximately $39,000. Balyasny Asset Management LLC purchased a new position in Crispr Therapeutics during the second quarter worth $5,165,000. BNP Paribas Arbitrage SA acquired a new position in shares of Crispr Therapeutics in the second quarter worth $41,000. Bank of New York Mellon Corp raised its holdings in shares of Crispr Therapeutics by 116.5% in the second quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock worth $1,559,000 after acquiring an additional 17,810 shares during the last quarter. Finally, First Trust Advisors LP purchased a new stake in shares of Crispr Therapeutics in the third quarter valued at $987,000. Institutional investors and hedge funds own 49.82% of the company’s stock.
Crispr Therapeutics stock opened at $59.44 on Friday. The firm has a market capitalization of $3.28 billion, a P/E ratio of -17.28 and a beta of 3.22. The stock has a fifty day moving average price of $65.98 and a 200 day moving average price of $51.14. Crispr Therapeutics AG has a 52 week low of $28.95 and a 52 week high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. As a group, equities analysts predict that Crispr Therapeutics AG will post 0.65 EPS for the current year.
A number of research firms recently commented on CRSP. Zacks Investment Research lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Oppenheimer boosted their target price on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, November 25th. Goldman Sachs Group upped their target price on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th. Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 price target on shares of Crispr Therapeutics in a research note on Monday, December 23rd. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $104.00 price target on shares of Crispr Therapeutics in a research note on Monday, December 16th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $71.38.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total transaction of $465,000.00. Following the sale, the director now directly owns 7,500 shares of the company’s stock, valued at $465,000. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,118 shares of company stock valued at $3,620,760. Corporate insiders own 21.40% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: Why are gap-down stocks important?
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crispr Therapeutics AG (NASDAQ:CRSP).
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.